Clinical Trial Update: Post-marketing Surveillance (Use Result Surveillance) With Refixia®

View source ↗

Summary

Completion of a post-marketing surveillance study of Refixia (recombinant factor IX-Fc fusion protein) in hemophilia B, summarizing observed safety outcomes fro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refixia (Nonacog Beta Pegol (N9-GP))

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Haemophilia B | Status: COMPLETED